Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Cunningham

Showing results (31-40 of 621) with videos related to

Pageof 63
Sort By:
Clinical Colorectal Cancer|May 6, 2005
Cetuximab in previously treated colorectal cancerNaureen Starling, David Cunningham
Seminars in Oncology|January 10, 2006
The role of cetuximab in the therapy of previously treated advanced colorectal cancerGeoff Chong, David Cunningham
Clinical Medicine (London, England)|January 25, 2013
Gastrointestinal oncology--what you need to knowElizabeth Smyth, David Cunningham
Lancet (London, England)|December 18, 2007
Adjuvant chemotherapy of colorectal cancerDavid Cunningham, Naureen Starling
The Journal of Family Practice|July 5, 2003
Metoclopramide reduces nausea from emergency contraceptionDavid Cunningham, Warren Newton
The Lancet. Oncology|June 2, 2009
Bevacizumab-associated gastrointestinal perforationIan Chau, David Cunningham
Clinical Colorectal Cancer|December 6, 2007
The role of epidermal growth factor receptor-targeted antibody therapy in previously treated colorectal cancerDavid Watkins, David Cunningham
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 13, 2008
Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodiesRachel Wong, David Cunningham
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Lymphocyte-predominant Hodgkin's lymphomaAlan Horwich, David Cunningham
Lancet (London, England)|April 19, 2023
Pembrolizumab plus chemotherapy as first-line treatment for advanced biliary tract cancerSusanna Slater, David Cunningham
Pageof 63

Showing results (31-40 of 621) with videos related to

Sort By:
Pageof 63
Clinical Colorectal Cancer|May 6, 2005
Cetuximab in previously treated colorectal cancerNaureen Starling, David Cunningham
Seminars in Oncology|January 10, 2006
The role of cetuximab in the therapy of previously treated advanced colorectal cancerGeoff Chong, David Cunningham
Clinical Medicine (London, England)|January 25, 2013
Gastrointestinal oncology--what you need to knowElizabeth Smyth, David Cunningham
Lancet (London, England)|December 18, 2007
Adjuvant chemotherapy of colorectal cancerDavid Cunningham, Naureen Starling
The Journal of Family Practice|July 5, 2003
Metoclopramide reduces nausea from emergency contraceptionDavid Cunningham, Warren Newton
The Lancet. Oncology|June 2, 2009
Bevacizumab-associated gastrointestinal perforationIan Chau, David Cunningham
Clinical Colorectal Cancer|December 6, 2007
The role of epidermal growth factor receptor-targeted antibody therapy in previously treated colorectal cancerDavid Watkins, David Cunningham
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 13, 2008
Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodiesRachel Wong, David Cunningham
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2010
Lymphocyte-predominant Hodgkin's lymphomaAlan Horwich, David Cunningham
Lancet (London, England)|April 19, 2023
Pembrolizumab plus chemotherapy as first-line treatment for advanced biliary tract cancerSusanna Slater, David Cunningham
Pageof 63